Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Do not call
En
Evonile Pharma Ltd. Share Price
Day's Range
Low
₹1,501.40
High
₹1,594.80
Price Summary
| Previous Close | ₹1,520.40 |
|---|---|
| Day's Range | ₹1,501.40 - ₹1,594.80 |
| Open | ₹1,589.60 |
| 52 Week Range | ₹799.42 - ₹2,178.46 |
| Volume | 47,355 |
| Market Cap | ₹0.01 |
| Previous Close | ₹1,510.00 |
|---|---|
| Day's Range | ₹1,503.90 - ₹1,585.80 |
| Open | ₹1,570.60 |
| 52 Week Range | ₹631.32 - ₹2,178.48 |
| Volume | 4,388 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 719.99 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.14 |
| P/E Ratio | 25.71 |
| Book Value(₹) | 3.34 |
| PAT Margin (%) | 24.72 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.34 |
| Trade Value ( ₹ in Lacs) | 66.26 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.14 |
| P/E Ratio | 25.71 |
| Book Value(₹) | 3.34 |
| PAT Margin (%) | 24.72 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.34 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 903.3 | 3562.7 |
| Expenses | N/A | N/A |
| PBT | 326.5 | 1304.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 242.2 | 1009.0 |
About Evonile Pharma Ltd.
| Founded | 1947 |
|---|---|
| Managing Director | Vikas Gupta |
| NSE Symbol | EVONILE |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Adani Enterprises Ltd. | 3,70,378.50 | 2,682.00 | 1,753.00 - 1,753.00 |
| Aditya Infotech Ltd. | 51,654.17 | 4,148.40 | 0.00 - 0.00 |
| Aegis Logistics Ltd. | 43,490.66 | 1,222.65 | 576.10 - 576.10 |
| Premier Energies Ltd. | 40,492.47 | 896.90 | 660.00 - 660.00 |
| Redington Ltd. | 28,034.43 | 348.00 | 191.31 - 191.31 |
| Honasa Consumer Ltd. | 16,173.71 | 501.75 | 248.40 - 248.40 |
| SG Mart Ltd. | 11,487.27 | 941.00 | 313.10 - 313.10 |
| Lloyds Enterprises Ltd. | 10,270.05 | 66.39 | 40.69 - 40.69 |
| Entero Healthcare Solutions Ltd. | 8,604.98 | 1,971.20 | 944.00 - 944.00 |
| Cello World Ltd. | 8,321.23 | 364.85 | 314.00 - 314.00 |
No Records Found
Latest News
Evonile Pharma informs about revised integrated filing
Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, Evonile Pharma has submitted the revised Integrated Filing (Financial) for the quarter and half year ended September 30, 2026, comprising the Unaudited Financial Statements together with the Limited Review Report thereon (Annexures I and II) and other disclosures forming part of the said filing. This revised filing is being submitted solely to rectify an inadvertent omission in the heading of the table appearing under ‘Disclosure of Outstanding Default on Loans and Debt Securities’ on page 2 of the disclosure submitted earlier on November 03, 2026, at 7:23 p.m. While the figures disclosed in the table were correctly stated, the expression ‘(INR in crores)’ was inadvertently omitted from the column heading. Accordingly, it has clarified that the amount disclosed against ‘A. Total amount outstanding as on date’ under ‘Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions’ should be read as ₹800 crores as on September 30, 2026. Further, the amount disclosed against ‘Total financial indebtedness of the listed entity including short-term and long-term debt’ should also be read as ₹800 crores. The company has confirmed that all other disclosures and particulars contained in the earlier submission remain unchanged. There is no change whatsoever in the Unaudited Financial Results, Limited Review Report, Related Party Transactions disclosure, or any other information forming part of the Integrated Filing (Financial). This revised filing is being made solely to correct the aforesaid omission in the table heading.
The above information is a part of company’s filings submitted to BSE.
Fabino Enterprises informs about SAST
Fabino Enterprise informs about SAST
Fabino Enterprises informs about updates
Aegis Logistics informs about analyst meet
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended, Aegis Logistics has informed that the Officials of the Company will be participating in Investor Meet on 18th November 2026 at Mumbai and will be meeting various investors in person. The copy of the Investor Presentation has been submitted to the Stock Exchanges and on the website of the Company www.aegisindia.com. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Evonile Pharma Ltd. is ₹1,520.40 as of 2026-11-13.
The market capitalisation of Evonile Pharma Ltd. is ₹5,539.22 as of 2026-11-12.
The 1-year return of Evonile Pharma Ltd. is % as of .
The P/E ratio of Evonile Pharma Ltd. is 25.71 as of 2026-11-13.
The 52-week high and low of Evonile Pharma Ltd. are ₹2,178.46 and ₹799.42, respectively, as of 2026-11-13.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
